Memorial Sloan-Kettering Cancer Center – Division of Thoracic Oncology
Department of Medicine
1275 York Avenue
New York, New York 10065
Dr. Lee M. Krug is an Assistant Attending Physician in the Division of Thoracic Oncology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center in New York, New York. In addition to mesothelioma, Dr. Krug’s clinical expertise includes small cell lung cancer, and other pulmonary neuroendocrine tumors, as well as non-small cell lung cancer. Dr. Krug is currently conducting several clinical trials with novel therapies. He has focused his research on clinical trials in non-small cell lung cancer, small cell lung cancer, and mesothelioma.
Dr. Krug earned his Bachelor of Science (B.S.) Degree in Biology from Emory University in Atlanta, Georgia. He attended Washington University School of Medicine in St. Louis, Missouri where he received his Medical Degree (M.D.). Dr. Krug completed his Internship at Johns Hopkins Hospital in Baltimore, Maryland. He continued on at Johns Hopkins Hospital in Baltimore to complete his Residency. Dr. Krug completed his Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York, New York, as well as his Chief Fellowship in Medical Oncology – also at Memorial Sloan-Kettering Cancer Center, NY.
He has served as faculty for the American Society of Clinical Oncology (ASSCO) and has presented original research at ASCO as well as world lung cancer meetings. Dr. Krug was awarded a career development award from the American Society of Clinical Oncology for his work on vaccines for small cell lung cancer.
Dr. Krug has dozens of published works to his credit including the recent: Treating Inoperable Non-Small Cell Lung Cancer: What Can We Do?
Dr. Krug’s other credits include but are not limited to the following:
Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007 Oct;2(10):957-65. PMID: 17909360 [PubMed – indexed for MEDLINE]
Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels. J Thorac Oncol. 2007 Oct;2(10):947-52. PMID: 17909358 [PubMed – indexed for MEDLINE]
The value of gamma camera and computed tomography data set coregistration to assess Lewis Y antigen targeting in small cell lung cancer by (111)Indium-labeled humanized monoclonal antibody 3S193. Eur J Radiol. 2007 Aug 20; [Epub ahead of print] PMID: 17714905 [PubMed – as supplied by publisher]
A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer. J Thorac Oncol. 2007 Jul;2(7):638-44. PMID: 17607120 [PubMed – indexed for MEDLINE]